A language takes work off your hands, gives it to a compiler, runtime, or toolchain, and charges you somewhere else.

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Recursion Pharmaceuticals reported mixed Q2 results, with a $7.67 million revenue drop and a narrowed net loss of $131.01 million. Despite these challenges, the company achieved key milestones in drug ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...